Published in Mov Disord on April 15, 2014
Compensation in Preclinical Huntington's Disease: Evidence From the Track-On HD Study. EBioMedicine (2015) 1.08
Attempted and successful compensation in preclinical and early manifest neurodegeneration - a review of task FMRI studies. Front Psychiatry (2014) 0.92
Preserving cortico-striatal function: deep brain stimulation in Huntington's disease. Front Syst Neurosci (2015) 0.91
Selective vulnerability of Rich Club brain regions is an organizational principle of structural connectivity loss in Huntington's disease. Brain (2015) 0.80
Introduction: the importance of cognition in movement disorders. Mov Disord (2014) 0.79
Abnormal cerebellar volume and corticocerebellar dysfunction in early manifest Huntington's disease. J Neurol (2015) 0.78
Huntington disease iPSCs show early molecular changes in intracellular signaling, the expression of oxidative stress proteins and the p53 pathway. Dis Model Mech (2015) 0.77
Abnormal Electrophysiological Motor Responses in Huntington's Disease: Evidence of Premanifest Compensation. PLoS One (2015) 0.76
Compensatory activation in fronto-parietal cortices among HIV-infected persons during a monetary decision-making task. Hum Brain Mapp (2016) 0.75
Health Care Delivery Practices in Huntington's Disease Specialty Clinics: An International Survey. J Huntingtons Dis (2016) 0.75
Assistive Technology for Cognition and Health-related Quality of Life in Huntington's Disease. J Huntingtons Dis (2016) 0.75
Problem solving, impulse control and planning in patients with early- and late-stage Huntington's disease. Eur Arch Psychiatry Clin Neurosci (2016) 0.75
Theory of Mind Is Impaired in Mild to Moderate Huntington's Disease Independently from Global Cognitive Functioning. Front Psychol (2017) 0.75
Striatal morphology correlates with frontostriatal electrophysiological motor processing in Huntington's disease: an IMAGE-HD study. Brain Behav (2016) 0.75
A stop-signal task for sheep: introduction and validation of a direct measure for the stop-signal reaction time. Anim Cogn (2017) 0.75
PIN1 Modulates Huntingtin Levels and Aggregate Accumulation: An In vitro Model. Front Cell Neurosci (2017) 0.75
Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol (2011) 4.98
Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol (2009) 3.82
Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol (2006) 3.57
Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol (2013) 3.56
Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol (2010) 3.47
PINK1-associated Parkinson's disease is caused by neuronal vulnerability to calcium-induced cell death. Mol Cell (2009) 3.17
Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol (2011) 2.99
A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J Exp Med (2008) 2.78
Psychiatric symptoms in Huntington's disease before diagnosis: the predict-HD study. Biol Psychiatry (2007) 2.71
PINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons. PLoS One (2008) 2.33
A contribution of cognitive decision models to clinical assessment: decomposing performance on the Bechara gambling task. Psychol Assess (2002) 2.32
Using cognitive models to map relations between neuropsychological disorders and human decision-making deficits. Psychol Sci (2005) 2.25
Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease. Brain (2007) 2.17
Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population. Am J Hum Genet (2013) 2.09
Disease-associated prion protein oligomers inhibit the 26S proteasome. Mol Cell (2007) 2.01
Oxytocin attenuates amygdala reactivity to fear in generalized social anxiety disorder. Neuropsychopharmacology (2010) 1.98
Genetic risk factors for variant Creutzfeldt-Jakob disease: a genome-wide association study. Lancet Neurol (2009) 1.94
Microglial activation in presymptomatic Huntington's disease gene carriers. Brain (2007) 1.93
Neurocognitive insights into substance abuse. Trends Cogn Sci (2005) 1.82
"Frontal" behaviors before the diagnosis of Huntington's disease and their relationship to markers of disease progression: evidence of early lack of awareness. J Neuropsychiatry Clin Neurosci (2010) 1.76
Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients. J Clin Invest (2015) 1.74
Motor abnormalities in premanifest persons with Huntington's disease: the PREDICT-HD study. Mov Disord (2009) 1.73
Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. J Proteome Res (2007) 1.59
Verbal episodic memory declines prior to diagnosis in Huntington's disease. Neuropsychologia (2007) 1.54
Gene expression in Huntington's disease skeletal muscle: a potential biomarker. Hum Mol Genet (2005) 1.51
White matter connections reflect changes in voluntary-guided saccades in pre-symptomatic Huntington's disease. Brain (2007) 1.47
Observing Huntington's Disease: the European Huntington's Disease Network's REGISTRY. PLoS Curr (2010) 1.45
Disease-related prion protein forms aggresomes in neuronal cells leading to caspase activation and apoptosis. J Biol Chem (2005) 1.42
Strategic and non-strategic problem gamblers differ on decision-making under risk and ambiguity. Addiction (2014) 1.42
The Prevalence of Huntington's Disease. Neuroepidemiology (2016) 1.40
Comparison of decision learning models using the generalization criterion method. Cogn Sci (2008) 1.40
Early changes in white matter pathways of the sensorimotor cortex in premanifest Huntington's disease. Hum Brain Mapp (2011) 1.39
Huntington's disease. BMJ (2010) 1.36
Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood. Proc Natl Acad Sci U S A (2007) 1.35
Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study. Hum Brain Mapp (2011) 1.32
Prevalence of adult Huntington's disease in the UK based on diagnoses recorded in general practice records. J Neurol Neurosurg Psychiatry (2013) 1.30
Hsa-miR-34b is a plasma-stable microRNA that is elevated in pre-manifest Huntington's disease. Hum Mol Genet (2011) 1.25
Specific psychiatric manifestations among preclinical Huntington disease mutation carriers. Arch Neurol (2007) 1.25
Targets for future clinical trials in Huntington's disease: what's in the pipeline? Mov Disord (2014) 1.21
Obsessive and compulsive symptoms in prediagnosed Huntington's disease. J Clin Psychiatry (2008) 1.17
Ten-year rate of longitudinal change in neurocognitive and motor function in prediagnosis Huntington disease. Mov Disord (2008) 1.16
Self-paced timing detects and tracks change in prodromal Huntington disease. Neuropsychology (2010) 1.16
Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease. Brain (2008) 1.16
Hypothalamic involvement in Huntington's disease: an in vivo PET study. Brain (2008) 1.15
Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease. Hum Mol Genet (2006) 1.15
Defective emotion recognition in early HD is neuropsychologically and anatomically generic. Neuropsychologia (2008) 1.15
Whole-brain atrophy as a measure of progression in premanifest and early Huntington's disease. Mov Disord (2009) 1.14
Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression. J Clin Invest (2012) 1.14
Enhanced negative priming in Parkinson's disease. Neuropsychology (2002) 1.14
HTT-lowering reverses Huntington's disease immune dysfunction caused by NFκB pathway dysregulation. Brain (2014) 1.13
Misfolded PrP impairs the UPS by interaction with the 20S proteasome and inhibition of substrate entry. EMBO J (2011) 1.13
Abnormal peripheral chemokine profile in Huntington's disease. PLoS Curr (2011) 1.12
Imaging microglial activation in Huntington's disease. Brain Res Bull (2006) 1.12
Mutant huntingtin impairs immune cell migration in Huntington disease. J Clin Invest (2012) 1.11
Functional compensation of motor function in pre-symptomatic Huntington's disease. Brain (2009) 1.11
Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease. J Neurol Neurosurg Psychiatry (2012) 1.11
Cognitive Mechanisms Underlying Risky Decision-Making in Chronic Cannabis Users. J Math Psychol (2010) 1.10
Mutant huntingtin causes defective actin remodeling during stress: defining a new role for transglutaminase 2 in neurodegenerative disease. Hum Mol Genet (2011) 1.10
The progression of regional atrophy in premanifest and early Huntington's disease: a longitudinal voxel-based morphometry study. J Neurol Neurosurg Psychiatry (2009) 1.09
Metabolic characterization of the R6/2 transgenic mouse model of Huntington's disease by high-resolution MAS 1H NMR spectroscopy. J Proteome Res (2006) 1.08
Huntington's disease: clinical presentation and treatment. Int Rev Neurobiol (2011) 1.07
C9orf72 expansions are the most common genetic cause of Huntington disease phenocopies. Neurology (2013) 1.06
Clinical impairment in premanifest and early Huntington's disease is associated with regionally specific atrophy. Hum Brain Mapp (2011) 1.05
Oxytocin enhances resting-state connectivity between amygdala and medial frontal cortex. Int J Neuropsychopharmacol (2012) 1.05
An event-based model for disease progression and its application in familial Alzheimer's disease and Huntington's disease. Neuroimage (2012) 1.04
Early atrophy of pallidum and accumbens nucleus in Huntington's disease. J Neurol (2010) 1.04
Brain-derived neurotrophic factor in patients with Huntington's disease. PLoS One (2011) 1.04
Bone marrow transplantation confers modest benefits in mouse models of Huntington's disease. J Neurosci (2012) 1.03
The application of NMR-based metabonomics in neurological disorders. NeuroRx (2006) 1.03
Hsp27 overexpression in the R6/2 mouse model of Huntington's disease: chronic neurodegeneration does not induce Hsp27 activation. Hum Mol Genet (2007) 1.03
Somatic and germline mosaicism in sporadic early-onset Alzheimer's disease. Hum Mol Genet (2004) 1.03
Juvenile Huntington's disease: a population-based study using the General Practice Research Database. BMJ Open (2013) 1.02
Medial frontal hyperactivity to sad faces in generalized social anxiety disorder and modulation by oxytocin. Int J Neuropsychopharmacol (2011) 1.02
Mouse models for neurological disease. Lancet Neurol (2002) 1.02
Prion diseases. J Neurovirol (2003) 1.02
Propensity for risk taking and trait impulsivity in the Iowa Gambling Task. Pers Individ Dif (2011) 1.00
Neurocognitive deficits related to poor decision making in people behind bars. Psychon Bull Rev (2008) 1.00
Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington's disease. J Neurosci (2012) 1.00
Irritability in pre-clinical Huntington's disease. Neuropsychologia (2009) 0.99
Huntington's disease phenocopies are clinically and genetically heterogeneous. Mov Disord (2008) 0.99
Oculomotor deficits indicate the progression of Huntington's disease. Prog Brain Res (2008) 0.98
Expressed Alu repeats as a novel, reliable tool for normalization of real-time quantitative RT-PCR data. Genome Biol (2010) 0.97
Motivational processes and autonomic responsivity in Asperger's disorder: evidence from the Iowa Gambling Task. J Int Neuropsychol Soc (2006) 0.96
Harnessing immune alterations in neurodegenerative diseases. Neuron (2009) 0.95
Altered brain mechanisms of emotion processing in pre-manifest Huntington's disease. Brain (2012) 0.95
Alternative fates of newly formed PrPSc upon prion conversion on the plasma membrane. J Cell Sci (2013) 0.93
Huntington's disease phenocopy syndromes. Curr Opin Neurol (2007) 0.93
Activation of conflicting responses in Parkinson's disease: evidence for degrading and facilitating effects on response time. Neuropsychologia (2005) 0.92
Abnormal motor cortex excitability in preclinical and very early Huntington's disease. Biol Psychiatry (2009) 0.92
Stability effects on results of diffusion tensor imaging analysis by reduction of the number of gradient directions due to motion artifacts: an application to presymptomatic Huntington's disease. PLoS Curr (2011) 0.92
The structural correlates of functional deficits in early huntington's disease. Hum Brain Mapp (2012) 0.92
Comparing the Iowa and soochow gambling tasks in opiate users. Front Neurosci (2012) 0.92
Visuomotor integration deficits precede clinical onset in Huntington's disease. Neuropsychologia (2010) 0.90
The structural involvement of the cingulate cortex in premanifest and early Huntington's disease. Mov Disord (2011) 0.90
The ubiquitin-proteasome system in neurodegeneration. Antioxid Redox Signal (2014) 0.90